Shebli Atrash, MD, discussed the current landscape of available BCMA-directed therapies for treating multiple myeloma.
Paul discussed common symptoms and typical treatments for the 2 adverse events.
The study has now dosed 8 patients in total.
Review top news and interview highlights from the week ending November 25, 2022.
The first participant has been followed-up for 3 months so far after treatment while the second is only 1 week post-treatment.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.